167 related articles for article (PubMed ID: 25203738)
21. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
Janbabai G; Oladi Z; Farazmandfar T; Taghvaei T; Naghshvar F
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1945-52. PubMed ID: 25820598
[TBL] [Abstract][Full Text] [Related]
22. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
23. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL; de Melo Gagliato D; Falchook GS; Janku F; Zinner R; Wheler JJ; Subbiah V; Piha-Paul SA; Fu S; Murphy MB; Ajani J; Tang C; Hess K; Hamilton SR; Roy-Chowdhuri S; Kurzrock R; Meric-Bernstam F; Hong DS
Oncotarget; 2014 Apr; 5(7):1837-45. PubMed ID: 24742823
[TBL] [Abstract][Full Text] [Related]
24. MET in gastric cancer--discarding a 10% cutoff rule.
Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
[TBL] [Abstract][Full Text] [Related]
25. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
Yang Y; Wang C; Dai C; Liu X; Li W; Huang M; Zhao X; Ji D; Li J; Guo W
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):547-557. PubMed ID: 33693450
[TBL] [Abstract][Full Text] [Related]
26. MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H; Okamoto I; Arao T; Okamoto W; Matsumoto K; Taniguchi H; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K; Yamada Y
Oncotarget; 2013 Jan; 4(1):9-17. PubMed ID: 23327903
[TBL] [Abstract][Full Text] [Related]
27. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
Matsusaka S; Wu AH; Cao S; Hanna DL; Chin K; Yang D; Zhang W; Ning Y; Stintzing S; Sebio A; Sunakawa Y; Stremitzer S; Yamauchi S; Okazaki S; Berger MD; Parekh A; Miyamoto Y; Mizunuma N; Lenz HJ
Pharmacogenomics J; 2018 Apr; 18(2):262-269. PubMed ID: 28398355
[TBL] [Abstract][Full Text] [Related]
29. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H; Okamoto I
Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
[TBL] [Abstract][Full Text] [Related]
30. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
31. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
32. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA‑34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET.
Wei B; Huang QY; Huang SR; Mai W; Zhong XG
Mol Med Rep; 2015 Oct; 12(4):5255-61. PubMed ID: 26238271
[TBL] [Abstract][Full Text] [Related]
34. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
[TBL] [Abstract][Full Text] [Related]
35. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.
Ha SY; Do IG; Lee J; Park SH; Park JO; Kang WK; Choi MG; Lee JH; Bae JM; Kim S; Kim KM; Sohn TS
Ann Surg Oncol; 2014 Apr; 21(4):1099-106. PubMed ID: 24306658
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma.
Ma J; Ma J; Meng Q; Zhao ZS; Xu WJ
Pathol Oncol Res; 2013 Oct; 19(4):821-32. PubMed ID: 23812675
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer.
Kim JG; Sohn SK; Chae YS; Cho YY; Bae HI; Yan G; Park JY; Lee MH; Chung HY; Yu W
Ann Oncol; 2007 Jun; 18(6):1030-6. PubMed ID: 17426061
[TBL] [Abstract][Full Text] [Related]
38. MDM2 is a useful prognostic biomarker for resectable gastric cancer.
Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
[TBL] [Abstract][Full Text] [Related]
39. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]